RESUMEN
Inhaled glucocorticoids (IGs) are today the first-line treatment for bronchial asthma. The systemic effects of inhaled glucocorticoids, such as suppressing the hypothalamic-pituitary-adrenal axis, are generally less than those with oral glucocorticoids. However, there is a long-term risk of adverse effects on bone. The objective of this piece was to review the published data on the effects of IGs on bone metabolism markers and bone mineral density in adults and in pediatric patients. The reviewed studies do not provide uniform results. Nevertheless, in general they suggest that IGs can affect metabolism and bone mineral density, especially: 1) when high doses are administered (more than 400 micrograms/day in children and more than 800 micrograms/day in adults), 2) in pediatric patients, in whom growth in stature can also be affected, 3) in patients whose intake of calcium and vitamin D is inadequate, and 4) in postmenopausal women not undergoing hormone replacement therapy. In general, at therapeutically equivalent doses, beclomethasone has a greater deleterious effect on bone than does budesonide, which in turn has more of an effect than does fluticasone. In addition to the obvious precaution of using the lowest effective dose, other proposed preventive measures include: 1) adequate instruction on the use of aerosols, 2) the use of large volume spacer devices, 3) rinsing the mouth after administering IGs, and 4) dietary adjustments or supplements in order to ensure an adequate intake of calcium and vitamin D.
Asunto(s)
Densidad Ósea/efectos de los fármacos , Huesos/efectos de los fármacos , Glucocorticoides/efectos adversos , Administración por Inhalación , Administración Oral , Administración Tópica , Adolescente , Adulto , Factores de Edad , Antiasmáticos/administración & dosificación , Antiasmáticos/efectos adversos , Antiinflamatorios/administración & dosificación , Antiinflamatorios/efectos adversos , Asma/tratamiento farmacológico , Beclometasona/administración & dosificación , Beclometasona/efectos adversos , Huesos/metabolismo , Broncodilatadores/administración & dosificación , Broncodilatadores/efectos adversos , Budesonida/administración & dosificación , Budesonida/efectos adversos , Niño , Preescolar , Ensayos Clínicos como Asunto , Femenino , Glucocorticoides/administración & dosificación , Humanos , Lactante , Persona de Mediana Edad , Factores de TiempoRESUMEN
Pericentric inversion of the human Y chromosome has an estimated frequency of the one per thousand. This inversion is always inherited but also is possible a de novo presentation. Sometimes this inverted chromosome is associated with the Down, Klinefelter and other chromosomal syndromes. For the carriers of pericentric inversion the risk of the mental retardation or multiple abortion is not apparently increase and there is not relation with abnormal phenotypic features. For some authors the pericentric inversion of the human Y chromosome is only a rare chromosomal heteromorphism.